| 1 |
Swedish experience-based value sets for EQ-5D health states
Kristina Burström, Sun Sun, Ulf‐G. Gerdtham et al. · Quality of Life Research
Open access |
21 Aug 2013 |
355 |
| 2 |
Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions
Rick A. Vreman, Inkatuuli Heikkinen, Ad Schuurman et al. · Value in Health
Open access |
6 Sep 2019 |
122 |
| 3 |
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Thomas D. Morel, Francis Arickx, Gustaf Befrits et al. · Orphanet Journal of Rare Diseases
Open access |
2013 |
122 |
| 4 |
Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
Mikael Svensson, Fredrik Olof Laurentius Nilsson, Karl Arnberg · PharmacoEconomics
|
20 Jun 2015 |
117 |
| 5 |
Personalizing health care: feasibility and future implications
Brian Godman et al. · BMC Medicine
Open access |
13 Aug 2013 |
102 |
| 6 |
MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
Ganna Oliynyk, María Victoria Ruiz-Pérez, Lourdes Sainero‐Alcolado et al. · iScience
Open access |
11 Oct 2019 |
100 |
| 7 |
Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
Björn Wettermark, Brian Godman, Martin Neovius et al. · Health Policy
|
30 Oct 2009 |
74 |
| 8 |
Access to Healthcare among People with Physical Disabilities in Rural Louisiana
Nina Davidsson, Björn Södergård · Social Work in Public Health
|
16 Mar 2016 |
70 |
| 9 |
Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI)
Jamie Elvidge et al. · Value in Health
Open access |
23 May 2024 |
67 |
| 10 |
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
Giovanni Tafuri, Margherita Pagnini, Jane Moseley et al. · British Journal of Clinical Pharmacology
Open access |
Jun 2016 |
64 |
| 11 |
Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
Konstantin Tachkov, Antal Tamás Zemplenyi, Maria Kamusheva et al. · Frontiers in Public Health
Open access |
14 Jul 2022 |
52 |
| 12 |
Real World Data in Health Technology Assessment of Complex Health Technologies
Milou A. Hogervorst, Johan Pontén, Rick A. Vreman et al. · Frontiers in Pharmacology
Open access |
10 Feb 2022 |
50 |
| 13 |
A median voter model of health insurance with ex post moral hazard
Johanna Jacob, Douglas Lundin · Journal of Health Economics
Open access |
29 Dec 2004 |
50 |
| 14 |
Why Did Drug Spending Increase During the 1990s?
Ulf‐G. Gerdtham, Douglas Lundin · PharmacoEconomics
|
2004 |
49 |
| 15 |
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Brian Godman et al. · Generics and Biosimilars Initiative Journal
Open access |
15 Jun 2019 |
45 |
| 16 |
Essential to increase the use of generics in Europe to maintain comprehensive health care?
Brian Godman, Marion Bennie, Christoph Baumgärtel et al. · Farmeconomia Health economics and therapeutic pathways
Open access |
5 Dec 2012 |
40 |
| 17 |
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
Giovanni Tafuri et al. · British Journal of Clinical Pharmacology
Open access |
25 Jan 2018 |
39 |
| 18 |
Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden
Brian Godman, Marie Persson, Jamilette Miranda et al. · Applied Health Economics and Health Policy
|
10 Jun 2013 |
33 |
| 19 |
Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making
Margreet G. Franken, Fredrik Olof Laurentius Nilsson, Frank Sandmann et al. · PharmacoEconomics
|
9 Jul 2013 |
30 |
| 20 |
On survival consumption costs – a reply to Nyman
Douglas Lundin, Joakim Ramsberg · Health Economics
|
21 Sep 2007 |
24 |
| 21 |
Assessment of the Swedish EQ-5D experience-based value sets in a total hip replacement population
Szilárd Nemes, Kristina Burström, Niklas Zethraeus et al. · Quality of Life Research
|
2 Jun 2015 |
21 |
| 22 |
Cost-Effectiveness of School-Based Prevention of Cannabis Use
Charlotte L. Deogan, Natalie Zarabi, Nils Stenström et al. · Applied Health Economics and Health Policy
|
13 May 2015 |
21 |
| 23 |
Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden
Joakim Ramsberg, Stefan Odeberg, Andreas Engstr�m et al. · The European Journal of Health Economics
|
21 Aug 2004 |
18 |
| 24 |
Low persistence of anticholinergic drug use in Sweden
Love Linnér, Helena Schiöler, Eva C. Samuelsson et al. · European Journal of Clinical Pharmacology
|
8 Nov 2010 |
18 |
| 25 |
Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future
Brian Godman et al. · Generics and Biosimilars Initiative Journal
Open access |
15 Sep 2015 |
15 |
| 26 |
The impact of health economic evaluations in Sweden
Emelie Heintz, Karl Arnberg, Lars‐Åke Levin et al. · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen
|
2014 |
14 |
| 27 |
Cost‐effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry
Fredrik Olof Laurentius Nilsson, Love Linnér, Eva C. Samuelsson et al. · British Journal of Urology
|
17 Nov 2011 |
14 |
| 28 |
Delayed payment schemes in Central-Eastern Europe and Middle-East
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh et al. · Frontiers in Medicine
Open access |
12 Aug 2022 |
13 |
| 29 |
Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers
Maria Kamusheva, Bertalan Németh, Antal Tamás Zemplenyi et al. · Journal of Comparative Effectiveness Research
Open access |
21 Jun 2022 |
12 |
| 30 |
The ageing of society, health services provision and taxes
Ulf‐G. Gerdtham, Douglas Lundin, María Sáez‐Martí · Journal of Population Economics
|
Sep 2005 |
10 |
| 31 |
Implementing a sandbox approach in health technology assessment: benefits and recommendations
Jamie Elvidge, Nick Crabb, Diana M. J. Delnoij et al. · International Journal of Technology Assessment in Health Care
Open access |
2024 |
9 |
| 32 |
Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe
Tuba Saygın Avşar, Jamie Elvidge, Claire Hawksworth et al. · Value in Health
Open access |
31 Jul 2024 |
9 |
| 33 |
Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision making
Ashley A. Jaksa, Alina N Pavel, Matti Aapro et al. · International Journal of Technology Assessment in Health Care
Open access |
2025 |
6 |
| 34 |
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Jacoline C. Bouvy, Pall F. Jonsson, Diana O'Rourke et al. · CNS Drugs
Open access |
22 Nov 2018 |
5 |
| 35 |
Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012)
Thomas D. Morel, Francis Arickx, Gustaf Befrits et al. · Value in Health
Open access |
22 Oct 2013 |
5 |
| 36 |
Variation in the prices of oncology medicines across Europe and the implications for the future
Brian Godman et al. · Generics and Biosimilars Initiative Journal
Open access |
15 Jun 2021 |
4 |
| 37 |
Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries
Zoltán Kaló et al. · Health Science Reports
Open access |
27 Jan 2026 |
3 |
| 38 |
Reimbursement Decisions for Pharmaceuticals in Sweden: the Impact of Cost-Effectiveness and Disease Severity
Fredrik Olof Laurentius Nilsson, Mikael Svensson, Karl Arnberg · Value in Health
Open access |
26 Oct 2014 |
3 |
| 39 |
Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation
Dominik Karres et al. · British Journal of Pharmacology
Open access |
22 Nov 2024 |
2 |
| 40 |
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained
Jonas Björnerstedt, Hannah Almqvist, Douglas Lundin et al. · Journal of Medical Economics
Open access |
16 Jan 2024 |
1 |
| 41 |
Patient preference of ostomy pouching systems – focus group interviews with stoma care patients
Björn Södergård, I. Tredal, I. Hemmingsson et al. · Value in Health
Open access |
May 2014 |
1 |
| 42 |
Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance
Luis Correia Pinheiro, Amanda C. Langston, Marie Orre et al. · Clinical Pharmacology & Therapeutics
Open access |
13 Aug 2026 |
0 |
| 43 |
Regulatory research priorities for AI use in the medicine lifecycle: a European perspective with global relevance
Luis Pinheiro, Amanda Langston, Marie Orre et al. · Zenodo (CERN European Organization for Nuclear Research)
Open access |
13 Aug 2026 |
0 |
| 44 |
The relationship between practice ownership and follow-up of comprehensive dental care. A Swedish register study
Bengt Franzon, Mikael Moutakis, Björn Axtelius et al. · Acta Odontologica Scandinavica
Open access |
16 Apr 2024 |
0 |
| 45 |
Cost-effectiveness in Swedish reimbursement decision making
Andreas Engström · European Journal of Pharmaceutical Sciences
|
30 Apr 2008 |
0 |
| 46 |
RE2 A Detailed Comparison of Dutch and Swedish Drug Reimbursement Decisions: What Evidence is Available, Which Criteria are Used, and is the Decision-Making Process Transparent?
Margreet G. Franken, Fredrik Olof Laurentius Nilsson, Frank Sandmann et al. · Value in Health
Open access |
29 Oct 2012 |
0 |
| 47 |
A comparative study of reimbursement application patterns between Iceland and Sweden
Fredrik Olof Laurentius Nilsson, Rúna Hauksdottir, Sveinbjorn Högnason · Journal of Pharmaceutical Health Services Research
|
Mar 2011 |
0 |